Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Prostate Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 101 articles: HTML format

Single Articles

November 2023
1. YAMAMOTO T, Umezawa R, Shimada S, Takahashi N, et al
   The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage Radiotherapy for Postoperative Prostate Cancer.
   Anticancer Res. 2023;43:5115-5125.
   PubMed     Abstract available
   
   
   October 2023
2. KANO H, Izumi K, Nakagawa R, Toriumi R, et al
   Role of Positive Biopsy Core Ratio in Prostate Cancer Patients.
   Anticancer Res. 2023;43:4619-4626.
   PubMed     Abstract available
   
   
   
3. NAGATA Y, Jojima K, Matsukawa T, Tomisaki I, et al
   Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
   Anticancer Res. 2023;43:4573-4581.
   PubMed     Abstract available
   
   
   
4. KUSUHARA Y, Fukawa T, Fukumori T, Ueno Y, et al
   Effect of Positive Biopsy Core Rate on Low-dose-rate Brachytherapy Outcomes in Intermediate-risk Prostate Cancer.
   Anticancer Res. 2023;43:4627-4635.
   PubMed     Abstract available
   
   
   
5. URABE F, Kobayashi D, Iwatani K, Imai YU, et al
   The Efficacy and Safety of a Low Relative Dose Intensity of Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer.
   Anticancer Res. 2023;43:4611-4617.
   PubMed     Abstract available
   
   
   September 2023
6. SISSUNG TM, Lochrin S, Liu T, Schmidt K, et al
   GNRH2 Polymorphism in Men With Prostate Cancer Treated With Androgen Deprivation Therapy.
   Anticancer Res. 2023;43:4023-4030.
   PubMed     Abstract available
   
   
   
7. KASHIWAGI E, Shiota M, Inokuchi J, Tsukahara S, et al
   Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies.
   Anticancer Res. 2023;43:4249-4254.
   PubMed     Abstract available
   
   
   
8. FERINI G, Zagardo V, Valenti V, Aiello D, et al
   Towards Personalization of Planning Target Volume Margins Fitted to the Abdominal Adiposity in Localized Prostate Cancer Patients Receiving Definitive or Adjuvant/Salvage Radiotherapy: Suggestive Data from an ExacTrac vs. CBCT Comparison.
   Anticancer Res. 2023;43:4077-4088.
   PubMed     Abstract available
   
   
   
9. FUJIMOTO N, Tsubonuma Y, Nagata Y, Minato A, et al
   Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.
   Anticancer Res. 2023;43:3841-3847.
   PubMed     Abstract available
   
   
   August 2023
10. OGATA T, Aizawa R, Nakamura K, Kobayashi T, et al
    Impact of Long-term Adjuvant Hormonal Therapy in High-dose IMRT for Unfavorable Locally Advanced Prostate Cancer.
    Anticancer Res. 2023;43:3589-3596.
    PubMed     Abstract available
    
    
    
11. HAAPASALMI S, Lehto JT, Metsanoja R, Kellokumpu-Lehtinen PI, et al
    End-of-life Decision-making Differs Between a Cancer and a Dementia Patient: Influences of the Physician's Background Factors.
    Anticancer Res. 2023;43:3631-3638.
    PubMed     Abstract available
    
    
    July 2023
12. SUZUKI H, Urabe F, Iwatani K, Miyajima K, et al
    Treatment Results of High-dose-rate Brachytherapy and External Beam Radiation With Long-term Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer.
    Anticancer Res. 2023;43:3135-3143.
    PubMed     Abstract available
    
    
    
13. ROCCA C, Rocca G, Zampieri P, Dell'atti L, et al
    Somatic and Germline Variants Affect Prognosis and Susceptibility in Prostate Cancer.
    Anticancer Res. 2023;43:2941-2949.
    PubMed     Abstract available
    
    
    
14. ENEI Y, Urabe F, Miki K, Suzuki H, et al
    Effect of Adequate Local Radiation Dose on Oncological Outcomes in Localized Prostate Cancer Patients Treated With Low-dose-rate Brachytherapy.
    Anticancer Res. 2023;43:3159-3166.
    PubMed     Abstract available
    
    
    June 2023
15. NATSAGDORJ A, Izumi K, Hiratsuka K, Naito R, et al
    The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
    Anticancer Res. 2023;43:2561-2569.
    PubMed     Abstract available
    
    
    
16. NOHL EK, Behring J, Kameri E, Koditz B, et al
    Improved Analysis of Prostate Cancer: VIM3, ATG7 and P53 Form a Complex and Activate miRNA 371a-3p.
    Anticancer Res. 2023;43:2407-2416.
    PubMed     Abstract available
    
    
    
17. SHIMADA T, Naito R, Toriumi R, Nakagawa R, et al
    Novel alpha-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells.
    Anticancer Res. 2023;43:2433-2444.
    PubMed     Abstract available
    
    
    
18. TAKAKUSAGI Y, Koge H, Kano K, Shima S, et al
    Safety of Carbon-ion Radiotherapy for Prostate Cancer After Rectal Cancer Surgery.
    Anticancer Res. 2023;43:2691-2695.
    PubMed     Abstract available
    
    
    May 2023
19. AL-SALOOL A, Soror T, Yu NY, Rades D, et al
    Prevalence and Risk Factors of Emotional Distress in Patients With Prostate Cancer Assigned to External-beam Radiotherapy With or Without High-dose Rate Brachytherapy.
    Anticancer Res. 2023;43:2103-2109.
    PubMed     Abstract available
    
    
    
20. AHREND H, Appel B, Jung L, Muller S, et al
    Reinforcement of the Tumor Suppressing Properties of microRNA-1 by Substitution at the C2' Position of Varying Ribose Residues in Chemically Synthesized microRNA-1 Molecules.
    Anticancer Res. 2023;43:1909-1918.
    PubMed     Abstract available
    
    
    
21. MATSUMOTO S, Matsufuji N, Koba Y, Tsuji H, et al
    In Vivo Dosimetry in the Urethra During Prostate Carbon Ion Radiotherapy.
    Anticancer Res. 2023;43:2259-2264.
    PubMed     Abstract available
    
    
    April 2023
22. MIYAJIMA K, Yanagisawa T, Suzuki H, Fukuokaya W, et al
    Comparison of Quality of Life and Injection Site Reactions After Switching from Degarelix 80 mg to 480 mg in Advanced Prostate Cancer: A Prospective Trial.
    Anticancer Res. 2023;43:1611-1621.
    PubMed     Abstract available
    
    
    
23. REZAC J, Hanouskova L, Vesely S, Kotaska K, et al
    Serum Thymidine Kinase 1 - Potential Prostate Cancer Biomarker: A Clinical Study.
    Anticancer Res. 2023;43:1675-1680.
    PubMed     Abstract available
    
    
    
24. YANG HC, Chang LW, Li JR, Wang SS, et al
    Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
    Anticancer Res. 2023;43:1809-1816.
    PubMed     Abstract available
    
    
    
25. AKINO Y, Shiomi H, Mabuchi N, Masai N, et al
    Optimization of Fluence Map for CyberKnife Raster Scanning Intensity Modulated Radiotherapy.
    Anticancer Res. 2023;43:1637-1642.
    PubMed     Abstract available
    
    
    March 2023
26. YAMASHITA SN, Tanaka Y, Kitagawa T, Baron B, et al
    Down-regulating Effect of a Standardized Extract of Cultured Lentinula edodes mycelia on Cortactin in Prostate Cancer Cells Is Dependent on Malignant Potential.
    Anticancer Res. 2023;43:1159-1166.
    PubMed     Abstract available
    
    
    
27. NAKAGAWA R, Iwamoto H, Naito R, Kadomoto S, et al
    Is it Necessary to Treat all Metastatic Prostate Cancer With Upfront Androgen Receptor Axis-targeted Agents?
    Anticancer Res. 2023;43:1351-1359.
    PubMed     Abstract available
    
    
    January 2023
28. TACHIBANA A, Hori S, Nakai Y, Miyake M, et al
    Effects on Life Expectancy of Treatment Decisions in Patients With Non-metastatic Prostate Cancer.
    Anticancer Res. 2023;43:473-483.
    PubMed     Abstract available
    
    
    
29. DE CICCO L, Marzoli L, Lorusso R, Mancuso RM, et al
    CBCT-based Prostate IGRT With and Without Implanted Markers: Assessment of Geometric Corrections and Time for Completion.
    Anticancer Res. 2023;43:405-408.
    PubMed     Abstract available
    
    
    
30. FURINI HH, Fukushima KSSQ, DE Nobrega M, DE Souza MF, et al
    An MGMT Allelic Variant Can Affect Biochemical Relapse in Prostate Cancer Patients.
    Anticancer Res. 2023;43:369-379.
    PubMed     Abstract available
    
    
    
31. NASCIMENTO-GONCALVES E, Seixas F, DA Costa RMG, Pires MJ, et al
    Appraising Animal Models of Prostate Cancer for Translational Research: Future Directions.
    Anticancer Res. 2023;43:275-281.
    PubMed     Abstract available
    
    
    
32. NAGATA Y, Matsukawa T, Tomisaki I, Fujimoto N, et al
    Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2023;43:429-436.
    PubMed     Abstract available
    
    
    
33. PALUMBO I, Ruggiero C, Festa E, DE Fano M, et al
    Bone Health Care Pathway for Non-metastatic Prostate Cancer Patients on Radiation and Androgen Deprivation Therapy.
    Anticancer Res. 2023;43:493-499.
    PubMed     Abstract available
    
    
    
34. XIAO H, Wu Z, Wang Q, Zhou C, et al
    Chalcone Derivatives Suppress Proliferation and Migration of Castration-resistant Prostate Cancer Cells Through FAK-mediated DNA Damage.
    Anticancer Res. 2023;43:389-403.
    PubMed     Abstract available
    
    
    
35. DELL'ATTI L, Aguiari G
    The Role of Genetic Polymorphisms in the Diagnosis and Management of Prostate Cancer: An Update.
    Anticancer Res. 2023;43:317-322.
    PubMed     Abstract available
    
    
    
36. LIAO CH, Chang WS, Hsu WL, Hu PS, et al
    Association of Matrix Metalloproteinase-7 Genotypes With Prostate Cancer Risk.
    Anticancer Res. 2023;43:381-387.
    PubMed     Abstract available
    
    
    
37. FERDA J, Hes O, Hora M, Ferdova E, et al
    Assessment of Prostate Carcinoma Aggressiveness: Relation to (68)Ga-PSMA-11-PET/MRI and Gleason Score.
    Anticancer Res. 2023;43:449-453.
    PubMed     Abstract available
    
    
    
38. CHANG LW, Wang SS, Yang CK, Lu K, et al
    Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia.
    Anticancer Res. 2023;43:485-491.
    PubMed     Abstract available
    
    
    
39. YAMAMICHI G, Kato T, Uemura M, Nonomura N, et al
    Diagnosing and Prognosing Bone Metastasis in Prostate Cancer: Clinical Utility of Blood Biomarkers.
    Anticancer Res. 2023;43:283-290.
    PubMed     Abstract available
    
    
    
40. YE L, Sanders AJ, Jiang WG
    Transglutaminase-4 (Prostate Transglutaminase), a Potential Biological Factor and Clinical Indicator for the Diagnosis and Prognosis of Prostate Cancer.
    Anticancer Res. 2023;43:291-296.
    PubMed     Abstract available
    
    
    
41. LI K, Luan Q, Zheng J, Li R, et al
    Clinical Value of Magnetic Resonance Imaging Combined With Serum Prostate-specific Antigen, Epithelial Cadherin and Early Prostate Cancer Antigen 2 In Diagnosis of Prostate Cancer.
    Anticancer Res. 2023;43:441-447.
    PubMed     Abstract available
    
    
    
42. NEUBERGER M, Frey L, Nitschke K, Wessels F, et al
    Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based Exploratory In Silico Analysis.
    Anticancer Res. 2023;43:417-428.
    PubMed     Abstract available
    
    
    
43. VALERIO MR, Serretta V, Arico D, Fazio I, et al
    A Prospective Observational Study on the Structuring Process and Implementation of a Large Regional, Inter-hospital, Virtual Multidisciplinary Tumor Board on Prostate Cancer.
    Anticancer Res. 2023;43:501-508.
    PubMed     Abstract available
    
    
    
44. DE LA PINTA C
    Radiotherapy in Prostate Brain Metastases: A Review of the Literature.
    Anticancer Res. 2023;43:311-315.
    PubMed     Abstract available
    
    
    
45. SUCKOW MA, Hiles MC
    Use of Conditioned Extracellular Matrix as a Tissue-engineered Tumor Matrisome for Prostate Cancer and Melanoma Immunotherapy.
    Anticancer Res. 2023;43:335-341.
    PubMed     Abstract available
    
    
    
46. LI PH, Liao CH, Huang WC, Chang WS, et al
    Association of Matrix Metalloproteinase-2 Genotypes With Prostate Cancer Risk.
    Anticancer Res. 2023;43:343-349.
    PubMed     Abstract available
    
    
    
47. LEECH M, Leijenaar RTH, Hompland T, Gaffney J, et al
    Exploring Hypoxia in Prostate Cancer With T2-weighted Magnetic Resonance Imaging Radiomics and Pimonidazole Scoring.
    Anticancer Res. 2023;43:351-357.
    PubMed     Abstract available
    
    
    
48. MASUDA H
    Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy.
    Anticancer Res. 2023;43:305-309.
    PubMed     Abstract available
    
    
    
49. FIALA O, Hosek P, Korunkova H, Hora M, et al
    Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience.
    Anticancer Res. 2023;43:463-471.
    PubMed     Abstract available
    
    
    
50. FAUSTINO-ROCHA AI, Jota-Baptista C, Nascimento-Goncalves E, Oliveira PA, et al
    Evolution of Models of Prostate Cancer: Their Contribution to Current Therapies.
    Anticancer Res. 2023;43:323-333.
    PubMed     Abstract available
    
    
    
51. COLBOURNE JRM, Toniolo JT, Diacon A, Lawrentschuk N, et al
    Following the Trend: A Comparative Analysis of Public Engagement and Funding for Annual Prostate and Breast Cancer Campaigns Using Google Trends.
    Anticancer Res. 2023;43:409-415.
    PubMed     Abstract available
    
    
    
52. MARTINO T, DE Bem GF, Santos SVM, Coelho MGP, et al
    LQB-118 Suppresses Migration and Invasion of Prostate Cancer Cells by Modulating the Akt/GSK3beta Pathway and MMP-9/Reck Gene Expression.
    Anticancer Res. 2023;43:359-367.
    PubMed     Abstract available
    
    
    
53. LEHRER S, Rheinstein PH
    Androgen Deprivation Therapy Unrelated to Alzheimer's Disease in the UK Biobank Cohort.
    Anticancer Res. 2023;43:437-440.
    PubMed     Abstract available
    
    
    
54. SCIALPI M, Martorana E, Scialpi P, Scalera GB, et al
    S-PI-RADS and PI-RRADS for Biparametric MRI in the Detection of Prostate Cancer and Post-treatment Local Recurrence.
    Anticancer Res. 2023;43:297-303.
    PubMed     Abstract available
    
    
    November 2022
55. TAMURA M, Ueda Y, Fukunaga JI, Kamima T, et al
    Impact of Knowledge-based Plan Model Improvement on Plan Complexity and Deliverability in VMAT For Prostate Cancer: A Multi-institutional Study.
    Anticancer Res. 2022;42:5305-5314.
    PubMed     Abstract available
    
    
    October 2022
56. LI JR, Wang SS, Chen CS, Yang CK, et al
    Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
    Anticancer Res. 2022;42:4857-4866.
    PubMed     Abstract available
    
    
    
57. OKABE KO, Terada N, Shirakawa T, Onizuka C, et al
    Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel.
    Anticancer Res. 2022;42:4981-4987.
    PubMed     Abstract available
    
    
    July 2022
58. NAKANISHI E, Hirata T, Tamari K, Isohashi F, et al
    Long-term Outcomes of Radiation Therapy for Prostate Cancer in Elderly Patients Aged >/=75 Years.
    Anticancer Res. 2022;42:3529-3536.
    PubMed     Abstract available
    
    
    
59. SHEN YC, Shih HJ, Lin CC, Huang SH, et al
    Synergistic Benefit of Adoptive T Cells in Combination With Chemoradiotherapy Against Metastatic Prostate Cancer Cells.
    Anticancer Res. 2022;42:3427-3434.
    PubMed     Abstract available
    
    
    
60. DENG F, Kong MX, Lai J
    Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and Prostate Adenocarcinoma Diagnosed in One Procedure.
    Anticancer Res. 2022;42:3601-3605.
    PubMed     Abstract available
    
    
    
61. NIEDER C, Stanisavljevic L
    Independent Validation of a Risk Stratification Model Predicting Survival in Patients With Metastatic Hormone-sensitive Prostate Cancer.
    Anticancer Res. 2022;42:3675-3679.
    PubMed     Abstract available
    
    
    June 2022
62. KAMIJIMA T, Yaegashi H, Mizokami A, Nakajima K, et al
    Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.
    Anticancer Res. 2022;42:3099-3108.
    PubMed     Abstract available
    
    
    
63. PEPE P, Pepe L, Cosentino S, Ippolito M, et al
    Detection Rate of (68)Ga-PSMA PET/CT vs. mpMRI Targeted Biopsy for Clinically Significant Prostate Cancer.
    Anticancer Res. 2022;42:3011-3015.
    PubMed     Abstract available
    
    
    
64. FUJIMOTO N, Minato A, Igawa T, Hiroshige T, et al
    Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
    Anticancer Res. 2022;42:3041-3047.
    PubMed     Abstract available
    
    
    
65. PASQUALETTI F, Calistri E, Fuentes T, Sainato A, et al
    Early Versus Late Postoperative Radiotherapy in Patients With Prostate Cancer: Results of a Single-centre Retrospective Study.
    Anticancer Res. 2022;42:2997-3001.
    PubMed     Abstract available
    
    
    May 2022
66. REINIKAINEN P, Kapanen M, Luukkaala T, Kellokumpu-Lehtinen PL, et al
    Acute Side-effects of Different Radiotherapy Treatment Schedules in Early Prostate Cancer.
    Anticancer Res. 2022;42:2553-2565.
    PubMed     Abstract available
    
    
    April 2022
67. IWAMOTO H, Nakagawa R, Makino T, Kadomoto S, et al
    Treatment Outcomes in Neuroendocrine Prostate Cancer.
    Anticancer Res. 2022;42:2167-2176.
    PubMed     Abstract available
    
    
    
68. FUJIWARA M, Fujiwara R, Oguchi T, Komai Y, et al
    Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy.
    Anticancer Res. 2022;42:2123-2130.
    PubMed     Abstract available
    
    
    
69. NEUBERGER M, Skladny J, Goly N, Wessels F, et al
    Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy.
    Anticancer Res. 2022;42:1911-1918.
    PubMed     Abstract available
    
    
    
70. KATSUTA M, Kimura T, Tashiro K, Murakami M, et al
    Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events.
    Anticancer Res. 2022;42:2023-2028.
    PubMed     Abstract available
    
    
    March 2022
71. PEPE P, Pennisi M
    Should 68Ga-PSMA PET/CT Replace CT and Bone Scan in Clinical Staging of High-risk Prostate Cancer?
    Anticancer Res. 2022;42:1495-1498.
    PubMed     Abstract available
    
    
    
72. MIZOKAMI A, Nishimoto K, Matsuyama H, Ichikawa T, et al
    Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice.
    Anticancer Res. 2022;42:1465-1475.
    PubMed     Abstract available
    
    
    
73. LIU C, Zhou Y, Zhou YU, Xu Z, et al
    Kindlin-3 in Immune Cells Is Required to Suppress Prostate Cancer Tumor Growth in Mice.
    Anticancer Res. 2022;42:1217-1220.
    PubMed     Abstract available
    
    
    February 2022
74. NAGATA Y, Matsukawa T, Tomisaki I, Fujimoto N, et al
    Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
    Anticancer Res. 2022;42:1107-1114.
    PubMed     Abstract available
    
    
    
75. SHIMADA T, Izumi K, Kano H, Kadomoto S, et al
    Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer.
    Anticancer Res. 2022;42:1065-1071.
    PubMed     Abstract available
    
    
    January 2022
76. IACOVELLI R, Ciccarese C, Caffo O, De Giorgi U, et al
    The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.
    Anticancer Res. 2022;42:165-172.
    PubMed     Abstract available
    
    
    
77. LEHTONEN M, Sormunen J, Hjalm-Eriksson M, Thellenberg-Karlsson C, et al
    Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.
    Anticancer Res. 2022;42:87-92.
    PubMed     Abstract available
    
    
    December 2021
78. XIE F, Peng F
    Reduction in Copper Uptake and Inhibition of Prostate Cancer Cell Proliferation by Novel Steroid-based Compounds.
    Anticancer Res. 2021;41:5953-5958.
    PubMed     Abstract available
    
    
    November 2021
79. BLAS L, Ieiri K, Shiota M, Nagakawa S, et al
    Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer.
    Anticancer Res. 2021;41:5593-5598.
    PubMed     Abstract available
    
    
    October 2021
80. KOPELKE S, Bartscht T, Schild SE, Tvilsted S, et al
    Frequency and Risk Factors of Sleep Disturbances in Patients With Prostate Cancer Assigned to Local or Loco-regional Radiotherapy.
    Anticancer Res. 2021;41:5165-5169.
    PubMed     Abstract available
    
    
    
81. TAKAI M, Kawakami K, Fujita Y, Kato T, et al
    Kartogenin Inhibits Prostate Cancer Cell Growth Through Smad2 Activation and Decreases Androgen Receptor Nuclear Localization.
    Anticancer Res. 2021;41:4753-4759.
    PubMed     Abstract available
    
    
    
82. FUJIMOTO N, Harada K, Shiota M, Tomisaki I, et al
    Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Anticancer Res. 2021;41:4687-4695.
    PubMed     Abstract available
    
    
    
83. KARLSSON S, Diaz Cruz MA, Faresjo M, Khamou AP, et al
    Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D3 in LNCaP Cells.
    Anticancer Res. 2021;41:4733-4740.
    PubMed     Abstract available
    
    
    September 2021
84. MASUDA H, Fujimoto A, Kanesaka M, Hou K, et al
    Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Japanese Patients With Prostate Cancer.
    Anticancer Res. 2021;41:4443-4446.
    PubMed     Abstract available
    
    
    
85. MIYATA Y, Masato M, Mukae Y, Nakamura Y, et al
    Pathological Roles of Prostaglandin E2-specific E-type Prostanoid Receptors in Hormone-sensitive and Castration-resistant Prostate Cancer.
    Anticancer Res. 2021;41:4333-4341.
    PubMed     Abstract available
    
    
    
86. JACEWICZ M, Rud E, Galtung KF, Noor D, et al
    Cancer Detection Rates in Targeted Transperineal MRI-TRUS Elastic Fusion-guided Prostate Biopsies Performed Under Local Anesthesia.
    Anticancer Res. 2021;41:4395-4400.
    PubMed     Abstract available
    
    
    August 2021
87. JIMENEZ ROMERO ME, Gallego MC, Navarro Serrato JC, Sanchez Hurtado MA, et al
    Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors.
    Anticancer Res. 2021;41:3955-3968.
    PubMed     Abstract available
    
    
    
88. BLAS L, Shiota M, Yamada S, Ieiri K, et al
    Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer.
    Anticancer Res. 2021;41:3885-3889.
    PubMed     Abstract available
    
    
    
89. WATANABE H, Kawakami A, Sato R, Watanabe K, et al
    Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
    Anticancer Res. 2021;41:3753-3758.
    PubMed     Abstract available
    
    
    
90. OELRICH F, Junker H, Stope MB, Erb HHH, et al
    Gelsolin Governs the Neuroendocrine Transdifferentiation of Prostate Cancer Cells and Suppresses the Apoptotic Machinery.
    Anticancer Res. 2021;41:3717-3729.
    PubMed     Abstract available
    
    
    
91. STELLER D, Simon R, VON Bialy R, Hakim SG, et al
    Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
    Anticancer Res. 2021;41:3917-3923.
    PubMed     Abstract available
    
    
    July 2021
92. HARADA J, Miyata Y, Taima T, Matsuda T, et al
    Stage-specific Embryogenic Antigen-4 Expression in Castration-resistant Prostate Cancer and its Correlation With the Androgen Receptor.
    Anticancer Res. 2021;41:3327-3335.
    PubMed     Abstract available
    
    
    
93. ERB HHH, Oster MA, Gelbrich N, Cammann C, et al
    Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System.
    Anticancer Res. 2021;41:3271-3279.
    PubMed     Abstract available
    
    
    June 2021
94. PEPE P, Pepe L, Pennisi M, Fraggetta F, et al
    Prostate Cancer Diagnosis and Management During One Year of the COVID-19 Pandemic.
    Anticancer Res. 2021;41:3127-3130.
    PubMed     Abstract available
    
    
    
95. GARRIDO MM, Ribeiro RM, Kruger K, Pinheiro LC, et al
    Are Proinflammatory Cytokines Relevant for the Diagnosis of Prostate Cancer?
    Anticancer Res. 2021;41:3067-3073.
    PubMed     Abstract available
    
    
    May 2021
96. ITO M, Sasamura K, Takase Y, Kotsuma T, et al
    Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer.
    Anticancer Res. 2021;41:2523-2531.
    PubMed     Abstract available
    
    
    
97. IINUMA K, Kawakami K, Mizutani K, Fujita Y, et al
    miRNA-93 in Serum Extracellular Vesicles Before and After Low Dose Rate Prostate Brachytherapy.
    Anticancer Res. 2021;41:2411-2418.
    PubMed     Abstract available
    
    
    April 2021
98. SEKITO S, Terabe T, Shibahara T, Onishi T, et al
    Usefulness of Biparametric Magnetic Resonance Imaging Combined With Prostate Specific Antigen Density in Pre-biopsy Detection of Clinically Insignificant Prostate Cancer.
    Anticancer Res. 2021;41:2183-2186.
    PubMed     Abstract available
    
    
    
99. FERINI G, Tripoli A, Molino L, Cacciola A, et al
    How Much Daily Image-guided Volumetric Modulated Arc Therapy Is Useful for Proctitis Prevention With Respect to Static Intensity Modulated Radiotherapy Supported by Topical Medications Among Localized Prostate Cancer Patients?
    Anticancer Res. 2021;41:2101-2110.
    PubMed     Abstract available
    
    
    
100. HAN Q, Hoffman RM
     Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.
     Anticancer Res. 2021;41:1921-1926.
     PubMed     Abstract available
     
     
     March 2021
101. NIEDER C, Mannsaker B, Yobuta R
     Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
     Anticancer Res. 2021;41:1471-1474.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.